Phase 3 Obesity Trial, Recruiting NCT06893016 Sponsor: Guangdong Raynovent Biotech Co., Ltd Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT06893016
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People with a body mass index (BMI) of 28 or above, OR a BMI between 24 and 28 who also have at least one weight-related health condition, such as: high blood pressure or use of blood pressure medication; abnormal cholesterol or triglyceride levels or use of cholesterol-lowering medication; obstructive sleep apnea (interrupted breathing during sleep); fatty liver; cardiovascular (heart) disease; or polycystic ovary syndrome (PCOS).
  • People who have tried at least once in the past to lose weight through diet and exercise without lasting success.

Who may not be able to join:

  • People whose weight gain is known to be caused by a specific genetic condition, another medical condition, or a medication.
  • People with a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC), or a condition called multiple endocrine neoplasia syndrome type 2.
  • People with a history of moderate to severe depression at any point in their life, a high score on a standard depression questionnaire (PHQ-9 score of 15 or above) at screening, or a history of bipolar disorder, schizophrenia, or other serious psychiatric conditions.
  • People who have previously had an organ transplant (except a corneal/eye transplant), or who are currently planning to have one.
  • People who plan to quit smoking during the study period.
  • People with a history of allergic reactions to multiple medications or foods, or who are known to be allergic to the study drug (RAY1225), GLP-1 receptor agonists, or related medications (confirm with trial site if unsure whether a specific allergy applies).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-10-8831-6815

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
15 June 2025
Est. completion
15 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percent Change From Baseline in Body Weight at Week 52; Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov